Merit Cudkowicz, en internationellt ledande ALS-expert tar plats i TikoMeds nybildade vetenskapliga råd 22 September, 2023 Read More »
Leading ALS authority Merit Cudkowicz joins TikoMed’s newly formed Scientific Advisory Board 22 September, 2023 Read More »
TikoMed’s ILB® inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia in vitro 21 September, 2022 Read More »
TikoMed’s drug candidate ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, providing further support for its broad spectrum mechanism of action 8 September, 2022 Read More »
New peer-reviewed research shows TikoMed’s ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including Amyotrophic Lateral Sclerosis 31 August, 2022 Read More »
TikoMed’s ILB® activates the body’s natural repair signals to restore glutamate homeostasis, amino acid metabolism and neurocognitive functions in a rat model of severe traumatic brain injury 3 August, 2022 Read More »
TikoMed AB reports positive phase II clinical data for the treatment of Amyothropic Lateral Sclerosis in data published by PLOS ONE 25 May, 2022 Read More »
TikoMed and IQVIA announce a strategic collaboration for the development of TIKOMED’s lead drug platform candidate ILB® 5 May, 2022 Read More »
TIKOMED’S ILB® attenuates clinical symptoms and serum biomarkers of oxidative/nitrosative stress and mitochondrial dysfunction in patients with ALS in data published by the Journal of Personalized Medicine 16 August, 2021 Read More »
First patient treated in TIKOMED’s Phase II study of clinical islet transplantation in patients with brittle diabetes 12 February, 2021 Read More »
TIKOMED’S ILB® resolves inflammatory scarring and promotes functional tissue repair in data published in npj Regenerative Medicine 26 January, 2021 Read More »
Update regarding our Amyotrophic Lateral Sclerosis (ALS) study conducted at Sahlgrenska University Hospital in Gothenburg, Sweden 9 October, 2020 Read More »
TIKOMED’S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants 14 September, 2020 Read More »
TIKOMED granted Orphan Medicinal Drug Designation for ILB® for the treatment of amyotrophic lateral sclerosis by the European Commission 28 August, 2020 Read More »
